2026 Q1 -tulosraportti
Vain PDF
16 päivää sitten
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
9 300
Myynti
Määrä
200
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | SSWM | ENS | ||
| 4 089 | NON | AVA | ||
| 4 000 | NON | NON | ||
| 1 632 | NON | NON | ||
| 155 | AVA | AVA |
Ylin
1,8VWAP
Alin
1,7VaihtoMäärä
0 19 876
VWAP
Ylin
1,8Alin
1,7VaihtoMäärä
0 19 876
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q2 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2026 Q1 -tulosraportti | 27.11. | |
| 2025 Q4 -tulosraportti | 28.8. | |
| 2025 Q3 -tulosraportti | 29.5. | |
| 2025 Q2 -tulosraportti | 27.2. | |
| 2025 Q1 -tulosraportti | 22.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenUS stocks are soaring on this news right now. https://www.cnbc.com/2025/12/12/cannabis-stocks-trump-regulations.html I wonder if it will have a ripple effect in Europe on Monday? FOMO?- ·1 päivä sittenHas anyone here looked closer at Cantourage Group SE O.N.? In my assessment, the company appears significantly undervalued. Cantourage is possibly the largest player in the German medical cannabis market, and one of the few that both operates in Germany and is simultaneously listed on the stock exchange. Nevertheless, the stock is traded at a market cap of approx. 300 million DKK (at a price of ~3.00 EUR). The company delivers strong revenue, runs a profitable business, and does it all through an extremely LEAN model: • no own production, and no ambitions to establish production, • focus on regulatory processes, sourcing and distribution, • in addition, also focus on this type of treatment via telemedicine. It is worth noting that Cantourage has not raised capital since their IPO in November 2022, but has nevertheless managed to maintain a solid financial position. If one were to point out a challenge, it has historically been their investor relations and communication to the market. This, however, seems to be changing. They recently hired Manuel Taverne in a brand new role as Head of Investor Relations — a function the company has not previously had. Cantourage itself writes: “With more than 20 years of experience in capital markets and strategic financial communications, Mr. Taverne brings deep expertise in building and maintaining strong investor relations. His appointment underlines Cantourage’s commitment to proactively advancing its capital markets strategy and fostering closer ties with institutional and private investors alike.” They have furthermore recently hired a new CFO, Monique Jaqqam. If they succeed in professionalizing their IR efforts, it could become very interesting for the stock. This is from their Q3-2025: - Revenue up 148% to EUR 75 million in the first nine months of 2025 (ca. 560 mDKK) - On track to become a European player – market liberalization in other European countries offers opportunities - Outlook – Focus on further growth and geographic diversification Berlin, 30 October 2025 – Cantourage Group SE continued its positive business development in the third quarter of 2025 and consolidated its position as one of the leading players in the European medical cannabis market, despite a challenging regulatory environment in Germany. In the third quarter of 2025, Cantourage generated revenue of around EUR 20.1 million (comparable period 2024: EUR 13.2 million). This resulted in total group revenue of around EUR 74.9 million at the end of the third quarter (comparable period 2024: EUR 30.2 million). EBITDA of roughly EUR 3.9 million (comparable period in 2024: EUR 2.1 million) at the end of Q3 2025 underscores the strong operating performance and high scalability of the business model. Disclaimer: I have personally taken a position in the company. Source: https://www.finanzwire.com/press-release/cantourage-group-se-etr-q3-2025-cantourage-delivers-strong-operating-performance-in-a-challenging-regulatory-market-environment-4KFiUufnE4I Company presentation (Feb 2025): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/67c9c5b90b00ad609be3b177_202502%20-%20Unternehmenspräsentation%20-%20Cantourage_EN.pdf
·24.7.A crappy stock from the beginning (IPO) to the end. Saved what could be saved today and exited. We are just being cheated out of our money and diluted by the management. Wish you all the best anyway. ...one less headache now 😉
·11.6.Notice of extraordinary general meeting of ODI Pharma AB (publ), 26 June 2025 at 14.30 • "Massive dilution of 15% of total shares at spot price - existing shareholders are being heavily diluted" • "Over 2.4 million new shares at 46-73% discount destroys value for us who paid full price" • "This is a disaster for minority shareholders" Insider trading and favoritism • "Chairman and CEO give themselves shares at spot price - this smells like insider trading" • "Why are only board members and close acquaintances allowed to buy shares so cheaply?" • "Classic 'crony capitalism' - those at the top enrich themselves at the expense of small shareholders" Financial desperation • "Urgent need for capital before the end of the year - the company is in financial crisis" • "73% discount screams desperation - no one wants to buy shares at market price" • "This is a cry for help from a company in financial trouble" Management credibility • "Management is unable to deliver results, so they are taking more money from shareholders" • "Previous issue failed - now they are trying again with even bigger discounts" • "The board does not take responsibility for poor performance, just asks for more money" Market signal and future prospects • "If their products were so good, why do they need constant capital injections?" • "The cannabis market in Europe is not as promising as they claimed" • "This signals that the business model is not working"
·28.7. · MuokattuI burned myself at Deutche Cannabis (100 percent bankrupt) a few years ago. I also burned myself at Wirecard. There have been movies made about those crooks. Is it as if Germany is a "cesspool" of crooks? They had Adolf there in their time too. But there are many honest and decent Germans by all means. Typical signs of crookedness are if it seems as if management is covering up for the longest time, regarding negative rumors. I think it was the British who saw through Wirecard then. Maybe some of these new leaders have different morals than what is common in business life? But I can't say anything about what substance is/is not found in ODI pharma. Strong price drift on small volumes today (a bit of a warning light in itself). But many people are doing medical cannabis in our modern times. Especially in Canada, but also the USA, the Netherlands, Israel.. probably more too
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
16 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenUS stocks are soaring on this news right now. https://www.cnbc.com/2025/12/12/cannabis-stocks-trump-regulations.html I wonder if it will have a ripple effect in Europe on Monday? FOMO?
- ·1 päivä sittenHas anyone here looked closer at Cantourage Group SE O.N.? In my assessment, the company appears significantly undervalued. Cantourage is possibly the largest player in the German medical cannabis market, and one of the few that both operates in Germany and is simultaneously listed on the stock exchange. Nevertheless, the stock is traded at a market cap of approx. 300 million DKK (at a price of ~3.00 EUR). The company delivers strong revenue, runs a profitable business, and does it all through an extremely LEAN model: • no own production, and no ambitions to establish production, • focus on regulatory processes, sourcing and distribution, • in addition, also focus on this type of treatment via telemedicine. It is worth noting that Cantourage has not raised capital since their IPO in November 2022, but has nevertheless managed to maintain a solid financial position. If one were to point out a challenge, it has historically been their investor relations and communication to the market. This, however, seems to be changing. They recently hired Manuel Taverne in a brand new role as Head of Investor Relations — a function the company has not previously had. Cantourage itself writes: “With more than 20 years of experience in capital markets and strategic financial communications, Mr. Taverne brings deep expertise in building and maintaining strong investor relations. His appointment underlines Cantourage’s commitment to proactively advancing its capital markets strategy and fostering closer ties with institutional and private investors alike.” They have furthermore recently hired a new CFO, Monique Jaqqam. If they succeed in professionalizing their IR efforts, it could become very interesting for the stock. This is from their Q3-2025: - Revenue up 148% to EUR 75 million in the first nine months of 2025 (ca. 560 mDKK) - On track to become a European player – market liberalization in other European countries offers opportunities - Outlook – Focus on further growth and geographic diversification Berlin, 30 October 2025 – Cantourage Group SE continued its positive business development in the third quarter of 2025 and consolidated its position as one of the leading players in the European medical cannabis market, despite a challenging regulatory environment in Germany. In the third quarter of 2025, Cantourage generated revenue of around EUR 20.1 million (comparable period 2024: EUR 13.2 million). This resulted in total group revenue of around EUR 74.9 million at the end of the third quarter (comparable period 2024: EUR 30.2 million). EBITDA of roughly EUR 3.9 million (comparable period in 2024: EUR 2.1 million) at the end of Q3 2025 underscores the strong operating performance and high scalability of the business model. Disclaimer: I have personally taken a position in the company. Source: https://www.finanzwire.com/press-release/cantourage-group-se-etr-q3-2025-cantourage-delivers-strong-operating-performance-in-a-challenging-regulatory-market-environment-4KFiUufnE4I Company presentation (Feb 2025): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/67c9c5b90b00ad609be3b177_202502%20-%20Unternehmenspräsentation%20-%20Cantourage_EN.pdf
- ·24.7.A crappy stock from the beginning (IPO) to the end. Saved what could be saved today and exited. We are just being cheated out of our money and diluted by the management. Wish you all the best anyway. ...one less headache now 😉
- ·11.6.Notice of extraordinary general meeting of ODI Pharma AB (publ), 26 June 2025 at 14.30 • "Massive dilution of 15% of total shares at spot price - existing shareholders are being heavily diluted" • "Over 2.4 million new shares at 46-73% discount destroys value for us who paid full price" • "This is a disaster for minority shareholders" Insider trading and favoritism • "Chairman and CEO give themselves shares at spot price - this smells like insider trading" • "Why are only board members and close acquaintances allowed to buy shares so cheaply?" • "Classic 'crony capitalism' - those at the top enrich themselves at the expense of small shareholders" Financial desperation • "Urgent need for capital before the end of the year - the company is in financial crisis" • "73% discount screams desperation - no one wants to buy shares at market price" • "This is a cry for help from a company in financial trouble" Management credibility • "Management is unable to deliver results, so they are taking more money from shareholders" • "Previous issue failed - now they are trying again with even bigger discounts" • "The board does not take responsibility for poor performance, just asks for more money" Market signal and future prospects • "If their products were so good, why do they need constant capital injections?" • "The cannabis market in Europe is not as promising as they claimed" • "This signals that the business model is not working"·28.7. · MuokattuI burned myself at Deutche Cannabis (100 percent bankrupt) a few years ago. I also burned myself at Wirecard. There have been movies made about those crooks. Is it as if Germany is a "cesspool" of crooks? They had Adolf there in their time too. But there are many honest and decent Germans by all means. Typical signs of crookedness are if it seems as if management is covering up for the longest time, regarding negative rumors. I think it was the British who saw through Wirecard then. Maybe some of these new leaders have different morals than what is common in business life? But I can't say anything about what substance is/is not found in ODI pharma. Strong price drift on small volumes today (a bit of a warning light in itself). But many people are doing medical cannabis in our modern times. Especially in Canada, but also the USA, the Netherlands, Israel.. probably more too
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
9 300
Myynti
Määrä
200
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | SSWM | ENS | ||
| 4 089 | NON | AVA | ||
| 4 000 | NON | NON | ||
| 1 632 | NON | NON | ||
| 155 | AVA | AVA |
Ylin
1,8VWAP
Alin
1,7VaihtoMäärä
0 19 876
VWAP
Ylin
1,8Alin
1,7VaihtoMäärä
0 19 876
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q2 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2026 Q1 -tulosraportti | 27.11. | |
| 2025 Q4 -tulosraportti | 28.8. | |
| 2025 Q3 -tulosraportti | 29.5. | |
| 2025 Q2 -tulosraportti | 27.2. | |
| 2025 Q1 -tulosraportti | 22.11.2024 |
Datan lähde: Quartr, FactSet
2026 Q1 -tulosraportti
Vain PDF
16 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q2 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2026 Q1 -tulosraportti | 27.11. | |
| 2025 Q4 -tulosraportti | 28.8. | |
| 2025 Q3 -tulosraportti | 29.5. | |
| 2025 Q2 -tulosraportti | 27.2. | |
| 2025 Q1 -tulosraportti | 22.11.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenUS stocks are soaring on this news right now. https://www.cnbc.com/2025/12/12/cannabis-stocks-trump-regulations.html I wonder if it will have a ripple effect in Europe on Monday? FOMO?
- ·1 päivä sittenHas anyone here looked closer at Cantourage Group SE O.N.? In my assessment, the company appears significantly undervalued. Cantourage is possibly the largest player in the German medical cannabis market, and one of the few that both operates in Germany and is simultaneously listed on the stock exchange. Nevertheless, the stock is traded at a market cap of approx. 300 million DKK (at a price of ~3.00 EUR). The company delivers strong revenue, runs a profitable business, and does it all through an extremely LEAN model: • no own production, and no ambitions to establish production, • focus on regulatory processes, sourcing and distribution, • in addition, also focus on this type of treatment via telemedicine. It is worth noting that Cantourage has not raised capital since their IPO in November 2022, but has nevertheless managed to maintain a solid financial position. If one were to point out a challenge, it has historically been their investor relations and communication to the market. This, however, seems to be changing. They recently hired Manuel Taverne in a brand new role as Head of Investor Relations — a function the company has not previously had. Cantourage itself writes: “With more than 20 years of experience in capital markets and strategic financial communications, Mr. Taverne brings deep expertise in building and maintaining strong investor relations. His appointment underlines Cantourage’s commitment to proactively advancing its capital markets strategy and fostering closer ties with institutional and private investors alike.” They have furthermore recently hired a new CFO, Monique Jaqqam. If they succeed in professionalizing their IR efforts, it could become very interesting for the stock. This is from their Q3-2025: - Revenue up 148% to EUR 75 million in the first nine months of 2025 (ca. 560 mDKK) - On track to become a European player – market liberalization in other European countries offers opportunities - Outlook – Focus on further growth and geographic diversification Berlin, 30 October 2025 – Cantourage Group SE continued its positive business development in the third quarter of 2025 and consolidated its position as one of the leading players in the European medical cannabis market, despite a challenging regulatory environment in Germany. In the third quarter of 2025, Cantourage generated revenue of around EUR 20.1 million (comparable period 2024: EUR 13.2 million). This resulted in total group revenue of around EUR 74.9 million at the end of the third quarter (comparable period 2024: EUR 30.2 million). EBITDA of roughly EUR 3.9 million (comparable period in 2024: EUR 2.1 million) at the end of Q3 2025 underscores the strong operating performance and high scalability of the business model. Disclaimer: I have personally taken a position in the company. Source: https://www.finanzwire.com/press-release/cantourage-group-se-etr-q3-2025-cantourage-delivers-strong-operating-performance-in-a-challenging-regulatory-market-environment-4KFiUufnE4I Company presentation (Feb 2025): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/67c9c5b90b00ad609be3b177_202502%20-%20Unternehmenspräsentation%20-%20Cantourage_EN.pdf
- ·24.7.A crappy stock from the beginning (IPO) to the end. Saved what could be saved today and exited. We are just being cheated out of our money and diluted by the management. Wish you all the best anyway. ...one less headache now 😉
- ·11.6.Notice of extraordinary general meeting of ODI Pharma AB (publ), 26 June 2025 at 14.30 • "Massive dilution of 15% of total shares at spot price - existing shareholders are being heavily diluted" • "Over 2.4 million new shares at 46-73% discount destroys value for us who paid full price" • "This is a disaster for minority shareholders" Insider trading and favoritism • "Chairman and CEO give themselves shares at spot price - this smells like insider trading" • "Why are only board members and close acquaintances allowed to buy shares so cheaply?" • "Classic 'crony capitalism' - those at the top enrich themselves at the expense of small shareholders" Financial desperation • "Urgent need for capital before the end of the year - the company is in financial crisis" • "73% discount screams desperation - no one wants to buy shares at market price" • "This is a cry for help from a company in financial trouble" Management credibility • "Management is unable to deliver results, so they are taking more money from shareholders" • "Previous issue failed - now they are trying again with even bigger discounts" • "The board does not take responsibility for poor performance, just asks for more money" Market signal and future prospects • "If their products were so good, why do they need constant capital injections?" • "The cannabis market in Europe is not as promising as they claimed" • "This signals that the business model is not working"·28.7. · MuokattuI burned myself at Deutche Cannabis (100 percent bankrupt) a few years ago. I also burned myself at Wirecard. There have been movies made about those crooks. Is it as if Germany is a "cesspool" of crooks? They had Adolf there in their time too. But there are many honest and decent Germans by all means. Typical signs of crookedness are if it seems as if management is covering up for the longest time, regarding negative rumors. I think it was the British who saw through Wirecard then. Maybe some of these new leaders have different morals than what is common in business life? But I can't say anything about what substance is/is not found in ODI pharma. Strong price drift on small volumes today (a bit of a warning light in itself). But many people are doing medical cannabis in our modern times. Especially in Canada, but also the USA, the Netherlands, Israel.. probably more too
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
9 300
Myynti
Määrä
200
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | SSWM | ENS | ||
| 4 089 | NON | AVA | ||
| 4 000 | NON | NON | ||
| 1 632 | NON | NON | ||
| 155 | AVA | AVA |
Ylin
1,8VWAP
Alin
1,7VaihtoMäärä
0 19 876
VWAP
Ylin
1,8Alin
1,7VaihtoMäärä
0 19 876
Välittäjätilasto
Dataa ei löytynyt